Northwest Biotherapeutics Announces Series of Financing Arrangements

BETHESDA, Maryland, June 6, 2011 -

- $3 Million Initial Funding, and Up To $25 Million Further Funding On
Fixed, Favorable Terms

Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put
in place a series of financing arrangements, including a $3 million
investment already received, and access to up to $25 million of further
funding on fixed, specified and favorable terms, at such times and in such
amounts as the Company chooses. This series of financing arrangements will
provide a strong financial foundation for completion of the Company's ongoing
240-patient clinical trial of DCVax(R)-L for the treatment of Glioblastoma
multiforme (GBM) brain cancer, and will also provide for certain other
programs in the Company's near term pipeline.

(Logo: photos.prnewswire.com/prnh/20110329/SF73084LOGO)

As the first component of the overall financing arrangements, the initial
$3 million investment has been provided by a multi-billion dollar
institutional investment fund based in Minnesota. The investment is
structured as a convertible note with warrants. The note is not convertible
until maturity, 18 months after closing, and is only convertible into
unregistered restricted stock at that time. The conversion price of the note
is a fixed, specified price per share, at a three percent (3%) discount from
the market price at the time of the note agreement (the volume weighted
average price over the 10 trading days ending on the May 31st closing date),
and the warrant coverage is one hundred percent without any cashless exercise
provision.

As such, this $3 million investment reflects a long-term interest in the
Company on the part of the investor, and will provide for the continued
acceleration of the Company's GBM brain cancer clinical trial while the
arrangements for the $25 million follow-on facility are being implemented.

"We are pleased to receive strong support and long-term interest from a
major institutional investor," commented Dr. Alton Boynton. "It reflects a
growing recognition in the investor community of NWBT's progress
operationally, and NWBT's significant growth potential."

As the second component of the overall financing arrangements, Toucan
Partners has agreed to provide an equity facility to enable NWBT to issue
registered, tradable shares for future financings of up to $25 million over a
30-month period. The shares involved in this equity facility will be
registered in several tranches, and the 30-month period will begin on the
effective date of the first registration statement.

Any use of this equity facility will be entirely in the Company's
discretion. If the Company elects to make maximum use of the facility, it can
potentially cover all of the remaining costs for the ongoing 240-patient GBM
brain cancer clinical trial to complete the patient enrollment and reach the
primary endpoint of the trial, as well as other near term initiatives.

Upon notification by the Company, Toucan will be obligated to purchase a
specified amount of stock based upon a backward-looking, fixed price formula
of ninety-five percent (95%) of the average of the three (3) lowest closing
bid prices of the Company's common stock during the fifteen (15) trading days
prior to the Company's notification date. Toucan will receive a one percent
(1%) commitment fee for the facility upon execution, and a five percent (5%)
fee on the sales of shares under the facility when the sales are executed.

"This equity facility marks an important step in taking control of our
own financing destiny, as it will enable us to access a much wider pool of
investors who have been expressing interest but can only invest in tradable
shares, while also providing the comfort of knowing that the equity facility
will be administered by a major shareholder whose interests are aligned with
the Company's," commented Dr. Alton Boynton. "The facility also affords us
substantially more favorable terms than have been available to us in
financings with unregistered shares or convertible debt."

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products that treat cancers more effectively than
current treatments, without toxicities of the kind associated with
chemotherapies, and on a cost-effective basis. The Company has a broad
platform technology for dendritic cell-based vaccines. The Company's lead
clinical trial is a 240-patient Phase II trial in newly diagnosed
Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain
cancer. The Company also previously received clearance from the FDA for a
612-patient Phase III trial in prostate cancer, and clearance from the FDA
for Phase I trials in five other cancers. The Company has also conducted a
Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer.

For further information about clinical sites and about the Company,
please visit the Company's web site at htpp://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts,
including statements concerning future treatment of patients with GBM using
DCVax(R)-Brain and future clinical trials, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "expects," "believes," "intends," and similar expressions are
intended to identify forward-looking statements. Actual results may differ
materially from those projected in any forward-looking statement.
Specifically, there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the Company's
ability to raise additional capital, risks related to the Company's ability
to enroll patients in its clinical trials and complete the trials on a timely
basis, the uncertainty of the clinical trials process, uncertainties about
the timely performance of third parties, and whether the Company's products
will demonstrate safety and efficacy. Additional information on these and
other factors, including Risk Factors, which could affect the Company's
results, is included in its Securities and Exchange Commission ("SEC")
filings. Finally, there may be other factors not mentioned above or included
in the Company's SEC filings that may cause actual results to differ
materially from those projected in any forward-looking statement. You should
not place undue reliance on any forward-looking statements. The Company
assumes no obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required by
securities laws.

Dr. Alton Boynton of Northwest Biotherapeutics, Inc., +1-425-503-6351